FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult Patients with HypoparathyroidismGlobeNewsWire • 10/31/22
Does Ascendis Pharma AS (ASND) Have the Potential to Rally 35% as Wall Street Analysts Expect?Zacks Investment Research • 10/12/22
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid TumorsGlobeNewsWire • 10/03/22
Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with HypoparathyroidismGlobeNewsWire • 08/31/22
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10GlobeNewsWire • 08/04/22
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare ConferenceGlobeNewsWire • 05/09/22
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in MayGlobeNewsWire • 05/01/22
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary EndpointsGlobeNewsWire • 03/13/22
Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/02/22
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2GlobeNewsWire • 02/25/22